Lilly Says It Didn't Give Up Alternatives By Narrowing Patent
When Eli Lilly & Co. narrowed a patent covering its cancer drug Alimta, it didn't give up the right to other hypothetical ways it could have narrowed the claims, the drugmaker...To view the full article, register now.
Already a subscriber? Click here to view full article